Skip to main content

Table 1 The laboratory data on admission

From: A 5-year recurrence-free survivor with over ten colorectal liver metastases undergoing FOLFOX plus bevacizumab followed by two-stage hepatectomy

WBC

7.5

×103/μl,

BUN

11.2

mg/dl

RBC

4.95

×106/μl

Creatinine

0.63

mg/dl

Hemoglobin

16.3

g/dL

Amylase

78

U/l

Hematocrit

48.6

%

Cholinesterase

270

U/l

Platelet

259

×103/μl

Na

141

mEq/l

PT activity

101

%

K

4.1

mEq/l

AST

21

U/l

Cl

106

mEq/l

ALT

12

U/l

CRP

0.38

mg/dl

ALP

428

U/l

Glucose

91

mg/dl

LDH

245

U/l

HbA1c

5.3

%

γ-GTP

20

U/l

CEA

189.1

ng/ml

Total bile acid

0.6

μmol/l

CA19-9

723.0

U/ml

Total protein

7.3

g/dl

HBs-Ag

(−)

 

Albumin

4.3

g/dl

HCV-Ab

(−)

 
  1. WBC white blood cell, RBC red blood cell, PT prothrombin time, AST aspartate aminotransferases, ALT alanine aminotransferases, ALP alkali phosphatase, LDH lactate dehydrogenase, γ-GTP γ-glutamyltransferase, BUN blood urea nitrogen, CRP C-reactive protein, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19–9, HBs-Ag hepatitis B surface antigen, HCV-Ab anti-hepatitis C antibody